

Ari M Melnick

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6259331/ari-m-melnick-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

412
papers

29,540
citations

88
h-index

165
g-index

428
ext. papers

35,144
ext. citations

11.1
avg, IF

6.6
L-index

#	Paper	IF	Citations
4 ¹²	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. <i>Cancer Cell</i> , 2010 , 18, 553-67	24.3	1933
4 ¹¹	IDH mutation impairs histone demethylation and results in a block to cell differentiation. <i>Nature</i> , 2012 , 483, 474-8	50.4	1393
4 ¹⁰	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2012 , 366, 1079-89	59.2	1378
4 ⁰⁹	Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. <i>Nature Biotechnology</i> , 2010 , 28, 848-55	44.5	949
4 ⁰⁸	methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. <i>Genome Biology</i> , 2012 , 13, R87	18.3	893
4 ⁰⁷	Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. <i>Cancer Cell</i> , 2011 , 20, 11-24	24.3	876
4 ⁰⁶	DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. <i>Cancer Cell</i> , 2010 , 17, 13-27	24.3	640
4 ⁰⁵	A molecular roadmap of reprogramming somatic cells into iPS cells. <i>Cell</i> , 2012 , 151, 1617-32	56.2	620
4 ⁰⁴	The N-methyladenosine (m ^A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. <i>Nature Medicine</i> , 2017 , 23, 1369-1376	50.5	584
4 ⁰³	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. <i>Nature Genetics</i> , 2012 , 44, 1179-81	36.3	552
4 ⁰²	EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. <i>Cancer Cell</i> , 2013 , 23, 677-92	24.3	547
4 ⁰¹	ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. <i>Cancer Cell</i> , 2012 , 22, 180-93	24.3	416
4 ⁰⁰	IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. <i>Nature</i> , 2012 , 488, 656-9	50.4	395
399	DNMT1-interacting RNAs block gene-specific DNA methylation. <i>Nature</i> , 2013 , 503, 371-6	50.4	379
398	Comparative isoschizomer profiling of cytosine methylation: the HELP assay. <i>Genome Research</i> , 2006 , 16, 1046-55	9.7	330
397	The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. <i>Science</i> , 2019 , 364,	33.3	300
396	Outcome of deferred initial therapy in mantle-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1209-13	27.0	270

395	MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. <i>Blood</i> , 2009 , 114, 3448-58	2.2	268
394	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 8368-73	11.5	255
393	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. <i>Nature Medicine</i> , 2004 , 10, 1329-35	50.5	251
392	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. <i>Nature Medicine</i> , 2015 , 21, 1199-208	50.5	247
391	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , 2015 , 21, 1344-9	50.5	231
390	A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. <i>Cancer Cell</i> , 2010 , 17, 400-11	24.3	230
389	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. <i>Blood</i> , 2010 , 116, 5247-55	2.2	227
388	Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. <i>PLoS Genetics</i> , 2012 , 8, e1002781	6	223
387	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016 , 22, 792-9	50.5	217
386	Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. <i>Molecular Cell</i> , 2003 , 12, 1551-64	17.6	211
385	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. <i>Nature Chemical Biology</i> , 2011 , 7, 818-26	11.7	208
384	Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. <i>Nature Immunology</i> , 2007 , 8, 705-14	19.1	200
383	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 5824-31	2.2	193
382	Translocations of the RARalpha gene in acute promyelocytic leukemia. <i>Oncogene</i> , 2001 , 20, 7186-203	9.2	190
381	Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1242-8	2.2	187
380	DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. <i>Cell Reports</i> , 2014 , 9, 1841-1855	10.6	183
379	MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. <i>Cancer Cell</i> , 2012 , 22, 812-24	24.3	182
378	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , 2009 , 113, 5536-48	2.2	179

377	Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. <i>Molecular and Cellular Biology</i> , 2002 , 22, 1804-18	4.8	177
376	Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. <i>Cancer Research</i> , 2014 , 74, 2520-32	10.1	170
375	The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. <i>Science</i> , 2011 , 333, 765-9	33.3	161
374	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , 2017 , 7, 38-53	24.4	159
373	BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. <i>Journal of Experimental Medicine</i> , 2015 , 212, 539-53	16.6	156
372	BCL6 enables Ph ⁺ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. <i>Nature</i> , 2011 , 473, 384-8	50.4	154
371	The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. <i>Molecular and Cellular Biology</i> , 1998 , 18, 5533-45	4.8	150
370	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. <i>Cancer Cell</i> , 2016 , 30, 197-213	24.3	150
369	ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. <i>Cancer Cell</i> , 2018 , 33, 495-511.e12	24.3	148
368	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016 , 538, 397-401	50.4	148
367	Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. <i>Cancer Cell</i> , 2015 , 27, 502-15	24.3	145
366	A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. <i>Blood</i> , 2009 , 113, 3397-405	2.2	142
365	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016 , 22, 1488-1495	50.5	140
364	Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. <i>Cancer Discovery</i> , 2013 , 3, 1002-19	24.4	140
363	The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. <i>Cell</i> , 2011 , 147, 554-64	56.2	139
362	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2011 , 208, 2163-74	16.6	138
361	Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. <i>Cancer Research</i> , 2013 , 73, 1232-44	10.1	137
360	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. <i>Nature Medicine</i> , 2009 , 15, 1369-76	50.5	136

359	Kaiso-deficient mice show resistance to intestinal cancer. <i>Molecular and Cellular Biology</i> , 2006 , 26, 199-208	136
358	High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. <i>Nucleic Acids Research</i> , 2009 , 37, 3829-39	20.1 133
357	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 125, 13-21	2.2 129
356	A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. <i>Cell Reports</i> , 2013 , 4, 578-88	10.6 127
355	The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. <i>Molecular and Cellular Biology</i> , 2000 , 20, 2075-86	4.8 125
354	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2010 , 116, e81-9	2.2 124
353	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , 2019 , 9, 546-563	24.4 123
352	Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. <i>Molecular Cell</i> , 2013 , 51, 766-79	17.6 123
351	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. <i>Blood</i> , 2010 , 116, 1025-34	2.2 120
350	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 3207-12	11.5 115
349	Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. <i>Trends in Molecular Medicine</i> , 2014 , 20, 343-52	11.5 114
348	Induction of sarcomas by mutant IDH2. <i>Genes and Development</i> , 2013 , 27, 1986-98	12.6 114
347	CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. <i>Cell Reports</i> , 2014 , 7, 1020-9	10.6 113
346	Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. <i>Molecular Cell</i> , 2008 , 29, 384-91	17.6 112
345	Histone deacetylase inhibitor treatment induces BRCAness and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. <i>Oncotarget</i> , 2014 , 5, 5637-50	3.3 110
344	Oncogene-mediated alterations in chromatin conformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 9083-8	11.5 110
343	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. <i>Blood</i> , 2007 , 110, 2067-74	2.2 110
342	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. <i>Science Translational Medicine</i> , 2016 , 8, 366ra161	17.5 109

341	Notch activation inhibits AML growth and survival: a potential therapeutic approach. <i>Journal of Experimental Medicine</i> , 2013 , 210, 321-37	16.6	109
340	DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. <i>Blood</i> , 2011 , 118, 3559-69	2.2	107
339	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. <i>Journal of Experimental Medicine</i> , 2015 , 212, 1819-32	16.6	106
338	A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. <i>Nature</i> , 2013 , 500, 93-7	50.4	103
337	Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. <i>Blood</i> , 2010 , 115, 4798-809	2.2	94
336	Pathogenic role of B-cell receptor signaling and canonical NF- κ B activation in mantle cell lymphoma. <i>Blood</i> , 2016 , 128, 82-92	2.2	92
335	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. <i>Cancer Cell</i> , 2019 , 36, 194-209.e9	24.3	92
334	Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. <i>Genome Research</i> , 2015 , 25, 478-87	9.7	92
333	Histone deacetylases as therapeutic targets in hematologic malignancies. <i>Current Opinion in Hematology</i> , 2002 , 9, 322-32	3.3	92
332	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3351-62	15.9	92
331	Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. <i>PLoS Genetics</i> , 2013 , 9, e1003137	6	91
330	Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. <i>PLoS Genetics</i> , 2011 , 7, e1001356	6	91
329	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , 2015 , 521, 357-61	50.4	90
328	The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. <i>Cell Metabolism</i> , 2012 , 15, 554-62	24.6	90
327	BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , 2010 , 207, 1209-21	16.6	89
326	Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. <i>Nature Immunology</i> , 2013 , 14, 380-8	19.1	88
325	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. <i>Journal of Clinical Investigation</i> , 2010 , 120, 4569-82	15.9	88
324	Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3099-111	15.9	88

323	EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. <i>Nature Communications</i> , 2017 , 8, 877	17.4	87
322	The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. <i>Clinical Cancer Research</i> , 2017 , 23, 885-893	12.9	85
321	Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. <i>Cancer Research</i> , 2008 , 68, 7258-63	10.1	83
320	A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. <i>Molecular Cell</i> , 2016 , 63, 711-719	17.6	83
319	Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. <i>Immunity</i> , 2016 , 45, 497-512	32.3	82
318	Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. <i>Science Translational Medicine</i> , 2014 , 6, 238ra71	17.5	82
317	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , 2013 , 19, 1014-22	50.5	82
316	Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. <i>Blood</i> , 2011 , 117, 234-41	2.2	82
315	SYK inhibition and response prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 118, 6342-52	2.2	82
314	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2015 , 27, 409-25	24.3	81
313	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015 , 6, 6921	17.4	81
312	Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 13360-5	11.5	79
311	Genetic and epigenetic heterogeneity in acute myeloid leukemia. <i>Current Opinion in Genetics and Development</i> , 2016 , 36, 100-6	4.9	79
310	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015 , 28, 114-28	24.3	78
309	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2018 , 8, 1632-1653	24.4	77
308	DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. <i>Genome Research</i> , 2013 , 23, 2030-41	9.7	75
307	The therapeutic landscape for cells engineered with chimeric antigen receptors. <i>Nature Biotechnology</i> , 2020 , 38, 233-244	44.5	75
306	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. <i>Nature Medicine</i> , 2016 , 22, 379-87	50.5	74

305	Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. <i>Blood</i> , 2009 , 113, 2795-804	2.2	74
304	An integrative genomic and epigenomic approach for the study of transcriptional regulation. <i>PLoS ONE</i> , 2008 , 3, e1882	3.7	72
303	BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. <i>Blood Cells, Molecules, and Diseases</i> , 2008 , 41, 95-9	2.1	71
302	Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. <i>Cancer Discovery</i> , 2012 , 2, 1004-23	24.4	70
301	Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. <i>Cancer Discovery</i> , 2017 , 7, 868-883	24.4	69
300	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in - and -Mutant Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2017 , 7, 494-505	24.4	68
299	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. <i>Cell Reports</i> , 2015 , 12, 2086-2096	19.8	68
298	Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation. <i>Blood</i> , 2014 , 123, 1012-20	2.2	68
297	Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. <i>Nature Immunology</i> , 2013 , 14, 437-45	19.1	67
296	CG dinucleotide clustering is a species-specific property of the genome. <i>Nucleic Acids Research</i> , 2007 , 35, 6798-807	20.1	67
295	Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. <i>Blood</i> , 2013 , 121, 5192-202	2.2	66
294	ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. <i>Blood</i> , 2004 , 103, 1454-63	2.2	66
293	Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution. <i>Journal of Visualized Experiments</i> , 2015 , e52246	1.6	65
292	Germinal center-derived lymphomas: The darkest side of humoral immunity. <i>Immunological Reviews</i> , 2019 , 288, 214-239	11.3	64
291	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E2219-28	11.5	64
290	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. <i>Nature Communications</i> , 2014 , 5, 3904	17.4	64
289	Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1286-98	15.9	64
288	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. <i>Blood</i> , 2014 , 123, 1699-708	2.2	63

287	B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. <i>Current Opinion in Hematology</i> , 2008 , 15, 381-90	3.3	60
286	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. <i>Nature Communications</i> , 2021 , 12, 1660	17.4	60
285	PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. <i>Cell Reports</i> , 2013 , 5, 1625-38	10.6	59
284	Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs. <i>Molecular Cell</i> , 2015 , 59, 89-103	17.6	56
283	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. <i>Nature</i> , 2021 , 589, 299-305	50.4	56
282	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020 , 10, 440-459	24.4	54
281	Epigenetics and B-cell lymphoma. <i>Current Opinion in Hematology</i> , 2011 , 18, 293-9	3.3	54
280	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. <i>Blood</i> , 2016 , 127, 858-68	2.2	54
279	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. <i>Nature Genetics</i> , 2017 , 49, 866-875	36.3	53
278	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. <i>Cancer Cell</i> , 2018 , 33, 44-59.e8	24.3	53
277	DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2016 , 6, 501-15	24.4	53
276	Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 12697-12702	11.5	52
275	DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. <i>Cancer Research</i> , 2010 , 70, 5840-50	10.1	51
274	Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions 2020 ,		51
273	Emerging epigenetic-modulating therapies in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 494-507	19.4	50
272	Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma. <i>Genome Medicine</i> , 2015 , 7, 110	14.4	50
271	Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. <i>Biomaterials</i> , 2015 , 73, 110-9	15.6	49
270	Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. <i>Nature Communications</i> , 2019 , 10, 821	17.4	49

269	New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. <i>Current Opinion in Immunology</i> , 2013 , 25, 339-46	7.8	48
268	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. <i>Blood</i> , 2013 , 121, 148-55	2.2	48
267	Dynamic evolution of clonal epialleles revealed by methclone. <i>Genome Biology</i> , 2014 , 15, 472	18.3	48
266	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROT. <i>Blood</i> , 2009 , 114, 5315-21	2.2	48
265	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. <i>Cancer Cell</i> , 2020 , 37, 655-673.e11	24.3	47
264	Downregulation of FOXP1 is required during germinal center B-cell function. <i>Blood</i> , 2013 , 121, 4311-20	2.2	47
263	The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. <i>Cell Reports</i> , 2014 , 8, 1497-508	10.6	46
262	SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. <i>Cancer Research</i> , 2016 , 76, 5467-78	10.1	46
261	Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. <i>Blood</i> , 2014 , 123, 3327-35	2.2	45
260	CtBP is an essential corepressor for BCL6 autoregulation. <i>Molecular and Cellular Biology</i> , 2008 , 28, 2175-86	4.6	45
259	Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. <i>Cancer Research</i> , 2013 , 73, 1076-85	10.1	44
258	The Impact of Heterogeneity on Single-Cell Sequencing. <i>Frontiers in Genetics</i> , 2019 , 10, 8	4.5	43
257	C/EBP β deregulation results in differentiation arrest in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4490-504	15.9	43
256	A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. <i>Cell Reports</i> , 2015 , 13, 2159-73	10.6	41
255	H1 histones control the epigenetic landscape by local chromatin compaction. <i>Nature</i> , 2021 , 589, 293-298	50.4	40
254	The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. <i>Blood</i> , 2004 , 103, 4650-8	2.2	39
253	Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. <i>PLoS ONE</i> , 2012 , 7, e40332	3.7	39
252	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. <i>Nature Immunology</i> , 2019 , 20, 86-96	19.1	39

251	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. <i>Nature Communications</i> , 2019 , 10, 1874	17.4	38
250	Negative regulation of osteoclast precursor differentiation by CD11b and α integrin-B-cell lymphoma 6 signaling. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 135-49	6.3	38
249	Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. <i>Journal of Biological Chemistry</i> , 2011 , 286, 25211-23	5.4	38
248	Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. <i>Cancer Cell</i> , 2019 , 36, 402-417.e13	24.3	37
247	Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. <i>Cancer Cell</i> , 2019 , 35, 916-931.e9	14.9	37
246	MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2018 , 8, 478-497	24.4	37
245	Central role of myeloid MCP1 in protecting against LPS-induced inflammation and lung injury. <i>Signal Transduction and Targeted Therapy</i> , 2017 , 2, 17066	21	37
244	BCL6 modulates tissue neutrophil survival and exacerbates pulmonary inflammation following influenza virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 11888-11893	11.5	35
243	Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2008 , 49, 874-82	1.9	35
242	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nature Communications</i> , 2018 , 9, 222	17.4	34
241	HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1158-67	15.9	34
240	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2015 , 125, 4559-71	15.9	34
239	Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. <i>PLoS ONE</i> , 2011 , 6, e18436	3.7	34
238	MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2017 , 77, 7038-7048	10.1	33
237	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4397-4412	15.9	33
236	Genetic and epigenetic inactivation of controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	32
235	The epigenetic basis of diffuse large B-cell lymphoma. <i>Seminars in Hematology</i> , 2015 , 52, 86-96	4	32
234	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. <i>Blood</i> , 2012 , 119, 5478-91	2.2	32

233	BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. <i>Journal of Biological Chemistry</i> , 2008 , 283, 22565-72	5.4	32
232	Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. <i>Best Practice and Research in Clinical Haematology</i> , 2003 , 16, 387-408	4.2	32
231	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. <i>Nature Communications</i> , 2016 , 7, 11889	17.4	32
230	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015 , 6, 6471	17.4	31
229	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. <i>Blood</i> , 2018 , 132, 2026-2039	2.2	31
228	H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. <i>Cancer Cell</i> , 2012 , 22, 194-208	24.3	31
227	LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. <i>British Journal of Haematology</i> , 2013 , 162, 621-30	4.5	30
226	Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. <i>Cancer Discovery</i> , 2021 , 11, 1542-1561	24.4	30
225	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. <i>Blood</i> , 2019 , 133, 2401-2412	2.2	29
224	Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. <i>Cellular and Molecular Bioengineering</i> , 2014 , 7, 394-408	3.9	29
223	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. <i>Cancer Cell</i> , 2021 , 39, 240-256.e11	24.3	29
222	Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 1125-32	5	28
221	NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. <i>Biology of Blood and Marrow Transplantation</i> , 2010 ,	4.7	28
220	Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. <i>Blood</i> , 2008 , 112, 644-51	2.2	28
219	The theoretical basis of transcriptional therapy of cancer: can it be put into practice?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3957-70	2.2	28
218	Specific peptides for the therapeutic targeting of oncogenes. <i>Current Opinion in Genetics and Development</i> , 2006 , 16, 71-7	4.9	28
217	miR-181a negatively regulates NF- κ B signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. <i>Blood</i> , 2016 , 127, 2856-66	2.2	28
216	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. <i>Cancer Discovery</i> , 2017 , 7, 506-521	24.4	27

215	BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements. <i>Blood</i> , 2013 , 121, 4551-4	2.2	27
214	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , 2021 , 11, 1468-1489	24.4	27
213	Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells. <i>Biomaterials</i> , 2019 , 198, 27-36	15.6	26
212	Sequential transcription factor targeting for diffuse large B-cell lymphomas. <i>Cancer Research</i> , 2008 , 68, 3361-9	10.1	26
211	The many layers of epigenetic dysfunction in B-cell lymphomas. <i>Current Opinion in Hematology</i> , 2016 , 23, 377-84	3.3	26
210	Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. <i>Blood</i> , 2018 , 132, 1265-1278	2.2	25
209	SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. <i>Journal of Biological Chemistry</i> , 2010 , 285, 3608-3616	5.4	25
208	Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. <i>Cancer Research</i> , 2009 , 69, 55-64	10.1	24
207	North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). <i>Blood</i> , 2015 , 126, 217-217	2.2	24
206	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. <i>Cell</i> , 2020 , 182, 297-316.e27	56.2	23
205	Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88, 231-45	7	23
204	Mechanisms of action of BCL6 during germinal center B cell development. <i>Science China Life Sciences</i> , 2015 , 58, 1226-32	8.5	23
203	Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. <i>Clinical Cancer Research</i> , 2010 , 16, 2435-42	12.9	23
202	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. <i>Cancer Discovery</i> , 2019 , 9, 872-889	24.4	22
201	Molecular pathways: targeting MALT1 paracaspase activity in lymphoma. <i>Clinical Cancer Research</i> , 2013 , 19, 6662-8	12.9	22
200	Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 7573-7588	8.3	22
199	Epigenetics in AML. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 463-8	4.2	21
198	Epigenetic therapy leaps ahead with specific targeting of EZH2. <i>Cancer Cell</i> , 2012 , 22, 569-70	24.3	20

197	Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. <i>Oncotarget</i> , 2016 , 7, 3520-32	3.3	20
196	Modular Immune Organoids with Integrin Ligand Specificity Differentially Regulate Ex Vivo B Cell Activation. <i>ACS Biomaterials Science and Engineering</i> , 2017 , 3, 214-225	5.5	19
195	How Biophysical Forces Regulate Human B Cell Lymphomas. <i>Cell Reports</i> , 2018 , 23, 499-511	10.6	19
194	BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. <i>Cancer Discovery</i> , 2019 , 9, 662-679	24.4	19
193	Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. <i>PLoS ONE</i> , 2008 , 3, e2965	3.7	18
192	Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. <i>Epigenomics</i> , 2016 , 8, 945-57	4.4	17
191	Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. <i>ACS Chemical Biology</i> , 2014 , 9, 1698-705	4.9	17
190	Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	17
189	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015 , 125, 2175-7	2.2	16
188	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. <i>Blood</i> , 2021 , 138, 370-381	2.2	16
187	AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. <i>Blood</i> , 2014 , 124, 437-437	2.2	15
186	is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. <i>Blood</i> , 2017 , 129, 1779-1790	2.2	14
185	A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. <i>JCI Insight</i> , 2016 , 1,	9.9	14
184	Multi-omic, Single-Cell, and Biochemical Profiles of Astronauts Guide Pharmacological Strategies for Returning to Gravity. <i>Cell Reports</i> , 2020 , 33, 108429	10.6	14
183	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019 , 133, 94-99	2.2	14
182	Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. <i>Cell Reports</i> , 2020 , 33, 108448	10.6	13
181	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. <i>IScience</i> , 2020 , 23, 101844	6.1	13
180	TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. <i>Science Advances</i> , 2020 , 6, eaay5872	14.3	12

179	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. <i>Blood</i> , 2013 , 122, 1-1	2.2	12
178	Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. <i>Blood Advances</i> , 2020 , 4, 5226-5231	7.8	12
177	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. <i>Nature Immunology</i> , 2021 , 22, 240-253	19.1	12
176	Quinoline and thiazolopyridine allosteric inhibitors of MALT1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019 , 29, 1694-1698	2.9	11
175	Peptide-based covalent inhibitors of MALT1 paracaspase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019 , 29, 1336-1339	2.9	11
174	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. <i>Nature Cancer</i> , 2020 , 1, 653-664	15.4	11
173	MTA2/NuRD Regulates B Cell Development and Cooperates with OCA-B in Controlling the Pre-B to Immature B Cell Transition. <i>Cell Reports</i> , 2019 , 28, 472-485.e5	10.6	11
172	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. <i>Genome Research</i> , 2020 , 30, 1217-1227	9.7	11
171	Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. <i>Cancer Research</i> , 2017 , 77, 1818-1830	10.1	10
170	Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. <i>Molecular Cell</i> , 2020 , 80, 845-861.e10	17.6	9
169	Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017 , 35, 397-407	1.3	8
168	Rationale for targeting BCL6 in -rearranged acute lymphoblastic leukemia. <i>Genes and Development</i> , 2019 , 33, 1265-1279	12.6	8
167	Differentiation therapy for IDH1/2 mutant malignancies. <i>Cell Research</i> , 2013 , 23, 975-7	24.7	8
166	Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML. <i>Cancer Discovery</i> , 2020 , 10, 1934-1949	24.4	8
165	Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. <i>Leukemia</i> , 2021 , 35, 1438-1450	10.7	8
164	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016 , 22, 578-9	50.5	7
163	An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. <i>Blood Cancer Discovery</i> , 2021 , 2, 70-91	7	7
162	The dangers of d μ vu: memory B cells as the cells of origin of ABC-DLBCLs. <i>Blood</i> , 2020 , 136, 2263-2274	2.2	7

161	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. <i>Blood</i> , 2021 , 138, 948-958	2.2	7
160	DNA Methylation-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2017 , 35, 793-795	2.2	6
159	Reprogramming Specific Gene Expression Pathways in B-Cell Lymphomas. <i>Cell Cycle</i> , 2005 , 4, 241-243	4.7	6
158	Clonal Hematopoiesis Before, During, and After Human Spaceflight. <i>Cell Reports</i> , 2020 , 33, 108458	10.6	6
157	Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 4333-4358	8.3	6
156	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. <i>Blood</i> , 2021 , 137, 788-800	2.2	6
155	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. <i>Nature Communications</i> , 2021 , 12, 5406	17.4	6
154	VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma. <i>Journal of Visualized Experiments</i> , 2015 , e53215	1.6	5
153	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age \geq 60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. <i>Blood</i> , 2016 , 128, 339-339	2.2	5
152	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. <i>Molecular and Cellular Biology</i> , 2000 , 20, 6550-6567	4.8	5
151	Role of chromosomal architecture in germinal center B cells and lymphomagenesis. <i>Current Opinion in Hematology</i> , 2019 , 26, 294-302	3.3	5
150	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020 , 10,	5.4	5
149	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). <i>Current Cancer Drug Targets</i> , 2021 , 21, 274-282	2.8	4
148	The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. <i>PLoS ONE</i> , 2020 , 15, e0231470	3.7	4
147	Discovering what makes STAT signaling TYK in T-ALL. <i>Cancer Discovery</i> , 2013 , 3, 494-6	24.4	3
146	BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL. <i>Blood</i> , 2020 , 136, 2-3	2.2	3
145	Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling. <i>Blood</i> , 2008 , 112, 757-757	2.2	3
144	ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. <i>Blood</i> , 2011 , 118, 405-405	2.2	3

143	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 1434-1434	2.2	3
142	Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. <i>Leukemia</i> , 2021 , 35, 3012-3016	10.7	3
141	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. <i>Blood</i> , 2021 , 137, 812-825	2.2	3
140	OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. <i>Nature Immunology</i> , 2021 , 22, 1327-1340	19.1	3
139	Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. <i>Cancer Research</i> , 2021 ,	10.1	3
138	System-wide transcriptome damage and tissue identity loss in COVID-19 patients.. <i>Cell Reports Medicine</i> , 2022 , 3, 100522	18	2
137	BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008 , 112, 295-295	2.2	2
136	Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008 , 112, 756-756	2.2	2
135	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2013 , 122, 634-634	2.2	2
134	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. <i>Blood</i> , 2014 , 124, 535-535	2.2	2
133	A Virtual B Cell Lymphoma Model to Predict Effective Combination Therapy. <i>Blood</i> , 2014 , 124, 928-928	2.2	2
132	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 306-306	2.2	2
131	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. <i>Blood</i> , 2016 , 128, 4088-4088	2.2	2
130	SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls. <i>Blood</i> , 2017 , 130, 643-643	2.2	2
129	Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival.. <i>Blood Cancer Discovery</i> , 2022 , 3, 50-65	7	2
128	Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML. <i>Blood</i> , 2021 , 138, 160-177	2.2	2
127	General Biomarker Recommendations for Lymphoma. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	2
126	An "EZ" Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?. <i>Cancer Discovery</i> , 2019 , 9, 1158-1160	24.4	2

125	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. <i>Leukemia</i> , 2021 , 35, 2688-2692	10.7	2
124	Untangling the Role of Polycomb Complexes in Chemotherapy Resistance. <i>Cancer Discovery</i> , 2018 , 8, 1348-1351	24.4	2
123	Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. <i>Frontiers in Immunology</i> , 2021 , 12, 688493	8.4	2
122	The SEQC2 epigenomics quality control (EpiQC) study. <i>Genome Biology</i> , 2021 , 22, 332	18.3	2
121	Untangling the Web of Lymphoma Somatic Mutations. <i>Cell</i> , 2017 , 171, 270-272	56.2	1
120	Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome. <i>Blood</i> , 2019 , 134, 23-23	2.2	1
119	Epigenetic Determinants of Pathogenesis and Resistance to Proteasome Inhibition in Mantle Cell Lymphoma.. <i>Blood</i> , 2008 , 112, 3373-3373	2.2	1
118	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. <i>Blood</i> , 2010 , 116, 851-851	2.2	1
117	LITAF, a BCL6 Target Gene, Regulates Autophagia in B Cells and Is Essential for T-Cell Dependent Humoral Responses. <i>Blood</i> , 2011 , 118, 1391-1391	2.2	1
116	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. <i>Blood</i> , 2011 , 118, 1479-1479	2.2	1
115	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013 , 122, 3736-3736	2.2	1
114	Deep Sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated With Relapse In B Cell Lymphomas. <i>Blood</i> , 2013 , 122, 79-79	2.2	1
113	BCL6 Orchestrates Tfh Differentiation Via Multiple Distinct Mechanisms. <i>Blood</i> , 2014 , 124, 4137-4137	2.2	1
112	BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain. <i>Blood</i> , 2014 , 124, 567-567	2.2	1
111	IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 788-788	2.2	1
110	AICDA Introduces Epigenetic Plasticity in Germinal Center-Derived Lymphomas and Accelerates Lymphomagenesis. <i>Blood</i> , 2016 , 128, 1045-1045	2.2	1
109	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas		1
108	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 1-10	1.9	1

107	Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts.. <i>American Journal of Hematology</i> , 2021 ,	7.1	1
106	EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis.. <i>Blood</i> , 2009 , 114, 3465-3465	2.2	1
105	BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.. <i>Blood</i> , 2009 , 114, 2167-2167	2.2	1
104	Development of Acute Megakaryoblastic Leukemia in Down Syndrome Is Associated with Sequential Epigenetic Changes That Target the Down Syndrome Critical Region on Chromosome 21,. <i>Blood</i> , 2011 , 118, 3451-3451	2.2	1
103	Conserved Transcriptional Deregulation Underlies GFI1 and ELANE Mutant Neutropenia. <i>Blood</i> , 2011 , 118, 13-13	2.2	1
102	Dynamic Changes Of DNA Methylation and a Functional Role For TET2 DNA Dioxygenase In Human Erythroid Differentiation. <i>Blood</i> , 2013 , 122, 3415-3415	2.2	1
101	Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 2499-2499	2.2	1
100	The Histone Demethylase LSD1 Acts As a BCL6 Corepressor In Germinal Center B Cells. <i>Blood</i> , 2013 , 122, 781-781	2.2	1
99	An Esrrb and Nanog Cell Fate Regulatory Module Controlled by Feed Forward Loop Interactions. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 630067	5.7	1
98	Dissecting bulk transcriptomes of diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021 , 39, 1305-1307	24.3	1
97	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.. <i>Science Translational Medicine</i> , 2022 , 14, eabb7695	17.5	1
96	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 805195	5.7	0
95	BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 202-202	2.2	0
94	Targeted detection and quantitation of histone modifications from 1,000 cells. <i>PLoS ONE</i> , 2020 , 15, e0240829	3.7	0
93	MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 269-269	2.2	0
92	Evolution of the Tumor Microenvironment throughout Progression and Transformation of EZH2 Mutant Follicular Lymphoma. <i>Blood</i> , 2021 , 138, 446-446	2.2	0
91	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. <i>Blood</i> , 2021 , 138, 413-413	2.2	0
90	BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells. <i>Blood</i> , 2021 , 138, 359-359	2.2	0

89	Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas. <i>Blood</i> , 2019 , 134, 2073-2073	2.2	o
88	EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche. <i>Blood</i> , 2019 , 134, 2768-2768	2.2	o
87	Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes,. <i>Blood</i> , 2011 , 118, 3725-3725	2.2	o
86	Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021 , 2, 198-200	7	o
85	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. <i>IScience</i> , 2021 , 24, 102651	6.1	o
84	Loss of function mutations of in classical Hodgkin lymphoma.. <i>Leukemia and Lymphoma</i> , 2021 , 1-11	1.9	o
83	3D chromosomal architecture in germinal center B cells and its alterations in lymphomagenesis.. <i>Current Opinion in Genetics and Development</i> , 2022 , 74, 101915	4.9	o
82	VII. Are lymphomas driven by epigenetic lesions?. <i>Hematological Oncology</i> , 2015 , 33 Suppl 1, 42-5	1.3	
81	The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 34-34	2.2	
80	Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 814216	5.7	
79	Complex Structural Variation Associated with Enhancer Hijacking and Loss of Tumor Suppressors in Mantle Cell Lymphoma. <i>Blood</i> , 2021 , 138, 675-675	2.2	
78	Sirtuin 3 Inhibition Targets AML Stem Cells through Perturbation of Fatty Acid Oxidation. <i>Blood</i> , 2021 , 138, 2240-2240	2.2	
77	A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006 , 108, 616-616	2.2	
76	Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.. <i>Blood</i> , 2007 , 110, 345-345	2.2	
75	m6a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia. <i>Blood</i> , 2017 , 130, 791-791	2.2	
74	HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. <i>Blood</i> , 2017 , 130, 645-645	2.2	
73	Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. <i>Blood</i> , 2018 , 132, 2854-2854	2.2	
72	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. <i>Blood</i> , 2019 , 134, 393-393	2.2	

71	Characterization of Complete Lncrnas Transcriptome Reveals Expression of Lncrnas As a Prognostic Factor and Linc-Smilo As a Potential Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4323-4323 ^{2,2}	
70	Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens. <i>Blood</i> , 2019 , 134, 173-173	2.2
69	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. <i>Blood</i> , 2019 , 134, 1239-1239	2.2
68	Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 787-787	2.2
67	PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells. <i>Blood</i> , 2014 , 124, 262-262	2.2
66	Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells. <i>Blood</i> , 2014 , 124, 1764-1764	2.2
65	BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 3570-3570	2.2
64	Conditional Loss of Dnmt3a Results in Myeloproliferation and Liver-Specific Myeloid Expansion. <i>Blood</i> , 2014 , 124, 364-364	2.2
63	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. <i>Blood</i> , 2014 , 124, 2963-2963	2.2
62	BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia. <i>Blood</i> , 2014 , 124, 513-513	2.2
61	Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 792-792	2.2
60	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 284-284	2.2
59	Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program. <i>Blood</i> , 2014 , 124, 836-836	2.2
58	DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 365-365	2.2
57	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. <i>Blood</i> , 2014 , 124, 69-69	2.2
56	Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression. <i>Blood</i> , 2014 , 124, 3565-3565	2.2
55	Whole-Genome Epigenomic Analysis in Multiple Myeloma Reveals DNA Hypermethylation of B-Cell Specific Enhancers. <i>Blood</i> , 2014 , 124, 2032-2032	2.2
54	Transcriptome Sequencing Reveals Thousands of Novel Long Non-Coding RNAs in B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 2427-2427	2.2

- 53 A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. *Blood*, **2015**, 126, 434-434 2.2
- 52 Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. *Blood*, **2015**, 126, 435-435 2.2
- 51 Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL. *Blood*, **2015**, 126, 1422-1422 2.2
- 50 Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 3716-3716 2.2
- 49 Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 556-556 2.2
- 48 Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. *Blood*, **2016**, 128, 735-735 2.2
- 47 Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia. *Blood*, **2016**, 128, 599-599 2.2
- 46 Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML. *Blood*, **2016**, 128, 2877-2877 2.2
- 45 RNA Interference Screen Implicates TNFAIP3 and FOXO1 in MALT1 Inhibition Resistance. *Blood*, **2016**, 128, 837-837 2.2
- 44 Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 1048-1048 2.2
- 43 Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-Rearranged Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 907-907 2.2
- 42 BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. *Blood*, **2016**, 128, 438-438 2.2
- 41 RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. *Blood*, **2016**, 128, 739-739 2.2
- 40 EZH2 Enables the Proliferation of Germinal Center B Cells and DLBCL through a Rb-E2F1 Positive Feedback Loop Involving Repression of CDKN1A. *Blood*, **2016**, 128, 734-734 2.2
- 39 Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma. *Blood*, **2008**, 112, 602-602 2.2
- 38 BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.. *Blood*, **2009**, 114, 765-765 2.2
- 37 Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.. *Blood*, **2009**, 114, 673-673 2.2
- 36 DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 707-707 2.2

35	BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.. <i>Blood</i> , 2009 , 114, 91-91	2.2
34	Promoter Hypermethylation in MLL-r Leukemia: Biology and Therapeutic Targeting.. <i>Blood</i> , 2009 , 114, 3472-3472	2.2
33	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. <i>Blood</i> , 2009 , 114, 619-619	2.2
32	STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. <i>Blood</i> , 2010 , 116, 705-705	2.2
31	BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 446-446	2.2
30	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. <i>Blood</i> , 2011 , 118, 1617-1617	2.2
29	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. <i>Blood</i> , 2011 , 118, 1406-1406	2.2
28	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. <i>Blood</i> , 2011 , 118, 438-438	2.2
27	Gene Risk Scores Based on Expression of 6 Genes Quantitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. <i>Blood</i> , 2011 , 118, 87-87	2.2
26	A Role for BCL6 in the Higher-Order Organization of Genes in DLBCL. <i>Blood</i> , 2011 , 118, 558-558	2.2
25	BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011 , 118, 562-562	2.2
24	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. <i>Blood</i> , 2011 , 118, 556-556	2.2
23	Genomewide Detection of Genes Targeted by Aberrant Somatic Hypermutation in Lymphoma,. <i>Blood</i> , 2011 , 118, 3474-3474	2.2
22	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. <i>Blood</i> , 2011 , 118, 585-585	2.2
21	MiR-181a Is a Master Regulator of the Nuclear Factor- κ B Signaling Pathway in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2012 , 120, 417-417	2.2
20	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. <i>Blood</i> , 2012 , 120, 1300-1300	2.2
19	H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 651-651	2.2
18	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. <i>Blood</i> , 2012 , 120, 776-776	2.2

- 17 Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. *Blood*, **2012**, 120, 1352-1352 2.2
- 16 Next Gen Dissection of Gfi1 Dependent Transcriptome in Myeloid Progenitors Reveals Global Control of Multiple Transcriptional Programs Including Coding and Non Coding RNAs. *Blood*, **2012**, 120, 111-111 2.2
- 15 Enhancer Profiling Reveals SOX9 As a Novel Transcription Regulator of B Cell Activation and DLBCL Transformation. *Blood*, **2012**, 120, 527-527 2.2
- 14 Lineage, Fusion Partner and Age Differences in the Methylome of MLL-r Leukemias. *Blood*, **2012**, 120, 3506-3506 2.2
- 13 Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). *Blood*, **2012**, 120, 64-64 2.2
- 12 High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. *Blood*, **2013**, 122, 3760-3760 2.2
- 11 The Bcl6 RD2 Domain Is Essential For Pre-Germinal Center B Cell Development. *Blood*, **2013**, 122, 783-783.2 2.2
- 10 Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. *Blood*, **2013**, 122, 229-229 2.2
- 9 Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. *Blood*, **2013**, 122, 72-72 2.2
- 8 Targeted detection and quantitation of histone modifications from 1,000 cells **2020**, 15, e0240829
- 7 Targeted detection and quantitation of histone modifications from 1,000 cells **2020**, 15, e0240829
- 6 Targeted detection and quantitation of histone modifications from 1,000 cells **2020**, 15, e0240829
- 5 Targeted detection and quantitation of histone modifications from 1,000 cells **2020**, 15, e0240829
- 4 Targeted detection and quantitation of histone modifications from 1,000 cells **2020**, 15, e0240829
- 3 Targeted detection and quantitation of histone modifications from 1,000 cells **2020**, 15, e0240829
- 2 Targeted detection and quantitation of histone modifications from 1,000 cells **2020**, 15, e0240829
- 1 Targeted detection and quantitation of histone modifications from 1,000 cells **2020**, 15, e0240829